JUBLPHARMA vs LAURUSLABS: Stock Comparison
LAURUS LABS is the larger company by market capitalisation. JUBILANT PHARMOVA shows a lower P/E, a higher dividend yield and faster revenue growth, while LAURUS LABS shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
JUBLPHARMA leads 6; LAURUSLABS leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | JUBLPHARMA | LAURUSLABS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | JUBLPHARMA | LAURUSLABS |
|---|---|---|
| Live Price | ₹924.5 | ₹1,840 |
| Day Change | 1.83% | -1.53% |
| Volume | 4.98 L | 10.76 L |
| 52-Week High | ₹1,183 | ₹1,949 |
| 52-Week Low | ₹786.05 | ₹823.1 |
| Distance from 52W High | -21.85% | -5.59% |
Valuation
| Metric | JUBLPHARMA | LAURUSLABS |
|---|---|---|
| Market Cap | ₹14,774 Cr | ₹99,406 Cr |
| P/E Ratio | 40.9x | 92x |
| P/B Ratio | 2.03x | 18.98x |
| EPS | ₹3.55 | ₹6.8 |
| Book Value | ₹445.48 | ₹100.53 |
| Dividend Yield | 0.57% | 0.1% |
Growth
| Metric | JUBLPHARMA | LAURUSLABS |
|---|---|---|
| Revenue Growth (TTM YoY) | 18.7% | 5.3% |
| EPS Growth (TTM YoY) | -22.4% | 19.4% |
| Qtr Sales Growth | 3,222.5% | 15.32% |
| Qtr Profit Growth | 672.6% | 24.87% |
Profitability & Leverage
| Metric | JUBLPHARMA | LAURUSLABS |
|---|---|---|
| ROE | 5.6% | 16.39% |
| ROCE | 6.19% | 13.68% |
| Net Margin | 5.28% | 13.76% |
| Operating Margin | 9.98% | 19.85% |
| Debt to Equity | 0.45x | 0.44x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | JUBLPHARMA | LAURUSLABS |
|---|---|---|
| Promoter Holding | 44.39% | 27.47%▼ 0.02 pp |
| FII Holding | 15.87%▼ 0.03 pp | 28%▲ 2.18 pp |
| DII Holding | 12.4%▲ 0.78 pp | 13.74%▼ 0.23 pp |
| Public Holding | 23.5%▼ 0.74 pp | 30.78%▼ 1.93 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: JUBILANT PHARMOVA and LAURUS LABS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.